UC San Diego has joined a Phase II clinical trial to evaluate various additional COVID-19 booster shots. The trial seeks to understand if different vaccine regimens can broaden immune responses in adults who already have received a primary vaccination series and a first booster shot.
Most immunocompromised people with a blood cancer called multiple myeloma benefited from a third dose of COVID-19 vaccines, a promising sign after it was shown that two doses tended to not be sufficient for them. However, some people with multiple myeloma still remained vulnerable and may need a fourth dose or antibody treatments as restrictions lift and new variants emerge, according to a fast-tracked study in Cancer Cell.
Indiana University will further develop a new technology for a combination oral rotavirus-norovirus vaccine for infants, thanks to a $1.2 million grant from venture capital firm GIVAX Inc.
Scientists analyzed ultrasounds for a wide range of birth defects from life-long and severe to short-term and mild
_RGB Blue20230706101098.jpg&width=400&height=400)
New research from the Case Western Reserve University (CWRU) School of Medicine suggests that the children younger than age 5 who are infected with the COVID-19 Omicron variant have less risk of severe health outcomes than those infected with the Delta variant.
In a paper in the journal Nature, Los Alamos National Laboratory scientists Bette Korber, Hyejin Yoon, Will Fischer and James Theiler, among nearly 130 authors from institutions around the world, describe their groundbreaking collaborative work, “Defining the risk of SARS-CoV-2 variants on immune protection.”
Many people who do not usually menstruate reported experiencing breakthrough bleeding or other period symptoms after receiving a COVID-19 vaccine, according to new findings from an online survey by researchers at Washington University in St. Louis.
Two new studies from the Global Virus Network (GVN) in partnership with the Petroleum Industry Health Organization of Iran provide evidence that getting the oral polio vaccine made from live, weakened poliovirus may protect people from COVID-19 infection by stimulating the immune system.
Transmission of SARS-CoV-2 has led to the ongoing global COVID-19 pandemic. By February 2022, more than 400 million have had confirmed COVID-19 and more than five million have died worldwide.
With second boosters becoming available, schedules for first boosters recently changed, and new evidence about the protection offered by boosters in the Omicron surge, a guide for those who have not yet been boosted or are considering a second booster.
Background: The development and approval of COVID-19 vaccines have generated optimism for the end of the COVID-19 pandemic and a return to normalcy. However, vaccine hesitancy, often fueled by misinformation, poses a major barrier to...
Vaccine uptake constitutes a key barometer as governments lead the communities out of the COVID-19 pandemic. Facts and fake news have apparently influenced vaccination willingness. But how valid is this proposition?
Reporters are invited to join a live discussion of research announcements at the forefront of the life sciences during a virtual press conference for the Experimental Biology (EB) 2022 meeting. The press conference will be held online from 11–11:45 a.m. Eastern on Friday, April 1, 2022 (RSVP by Thursday, March 31).
Board-certified dermatologist provides the latest information on how COVID and its vaccines affect people’s skin
Vaccination against COVID-19 during pregnancy is not associated with a higher risk of pregnancy complications, according to a large-scale registry study from Karolinska Institutet in Sweden and the Norwegian Institute of Public Health published in the journal JAMA.
Despite daily contact with Covid-19 patients early in the pandemic, some health professionals avoided falling ill. As a University of Gothenburg study shows, the explanation appears to be an antidote in the immune system: IgA antibodies to COVID-19.
Pancreatic cancer is notoriously difficult to cure or even treat. Now, a new strategy devised by scientists at Albert Einstein College of Medicine has succeeded in making pancreatic tumors visible to the immune systems of mice and vulnerable to immune attack, reducing cancer metastases by 87%. The paper describing the findings published online today in Science Translational Medicine.
The new study suggests that children tend to have strong antibody responses after SARS-CoV-2 infection. Understanding antibody responses to SARS-CoV-2 at different ages can inform COVID-19 vaccine strategies and policies.
The dramatic toll that COVID-19 has taken on the U.S. is apparent, but as caseloads come down and mandates are loosened it has become increasingly obvious how much of an impact the pandemic had on food service workers in industries like the fisheries. A study from the University of New Hampshire looked at the direct and indirect effects of the global pandemic on U.S. seafood workers by tracking cases and outbreaks and found seafood workers were twice as likely to contract COVID-19 as workers in other food industries.
A team of clinical investigators at the Icahn School of Medicine at Mount Sinai has announced the launch of a Phase 1, open-label, placebo-controlled study to evaluate the safety and immunogenicity of an egg-based COVID-19 vaccine in healthy, vaccinated adults who have never been infected with COVID-19.
Our immune protection is provided by two systems working hand in hand. When infected with a virus, the immune system reacts by producing antibodies that can prevent the virus from infecting further cells.
An antiviral drug used to treat SARS-CoV-2 remains effective against the newest variants of the evolving virus, according to Rutgers researchers. The study, published in the journal Cell Research, is one of the first to explore the full extent of SARS-CoV-2 mutations.
A study of more than eight million people published by The BMJ today finds no increased risk of rare neurological events after covid-19 vaccination.
Patients with impaired immunity have faced a difficult predicament during the pandemic. Their condition places them at risk of severe Covid-19 complications, but until now, no-one knew if they were at higher risk of adverse side-effects following vaccination against Covid-19. A new study trialed two mRNA vaccines in such patients and found that they are safe and well tolerated. The results will help immunocompromised patients in making an informed choice about vaccination.
As mask mandates disappear across the U.S., many are eager to return to pre-pandemic life. But scientists warn against letting down our guard too soon, pointing out that new variants could arise in the months ahead.
In a JAMA perspective piece, leading infectious disease researchers call for a coordinated response to HIV and COVID-19 globally, building on the successes of key donor programs such as the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) program and Global Fund to Fight AIDS, TB and Malaria (GFATM).
Newly released data from an ongoing research study at the University of Arizona Health Sciences in combination with the Center for Disease Control and Prevention’s PROTECT study show that the Pfizer-BioNTech COVID-19 vaccine has been a moderately effective tool for preventing the spread of COVID-19 and reducing the severity of infection among children and adolescents.
Using mRNA technology like that in the COVID-19 vaccines, researchers have demonstrated a successful way to deliver a potential HIV vaccine, researchers at Duke Human Vaccine Institute report.
The parasites that cause a disfiguring skin disease affecting about 12 million people globally may have met their match in vaccines developed using CRISPR gene-editing technology, new research suggests.
Financial incentives and other nudges have been used to help increase vaccination rates across the nation, but new research from the University of California San Diego’s Rady School of Management reveals that compensations need to be large—at least $100—to reduce vaccine hesitancy.
The first 12 study participants have been enrolled in a new Phase 1 clinical trial using the messenger ribonucleic acid (mRNA) vaccine technology developed by Moderna. The study evaluates the safety of and immune responses to three different experimental vaccines against HIV. This randomized, open-label trial represents one of the first clinical studies of the use of mRNA vaccine technology against HIV.
Briefly blocking a key molecule when administering the only approved vaccine for tuberculosis vastly improves long-term protection against the devastating disease in mice, researchers from Texas Biomedical Research Institute report this week in the Journal of Immunology.
With mask mandates being lifted and case counts dropping, University of Michigan experts reflect on living with ongoing COVID-19.
McMaster researchers have been able to re-engineer red blood cells and use them as a promising new vehicle for vaccine delivery.
They were the first to answer the call in March 2020. Here, several University of Michigan Health faculty and staff members reflect on their personal and professional experiences during the pandemic, sharing hardships most may not have felt or seen outside of the hospital walls.
The antiviral therapies remdesivir, molnupiravir, and the active ingredient in Pfizer’s Paxlovid pill (nirmatrelvir), remain effective in laboratory tests against the BA.2 variant of SARS-CoV-2, the virus that causes COVID-19. The BA.2 variant also remains susceptible to at least some of the monoclonal antibodies used to treat COVID-19, such as Evusheld by AstraZeneca.
mRNA vaccines are highly effective in preventing covid-19 associated hospital admissions related to the alpha, delta, and omicron variants.
The study, led by Moffitt Cancer Center, followed 515 patients with varying cancers. The goal was to evaluate if patients had an immune response to the Moderna mRNA-1273 vaccine and if that response differed by diagnosis and treatment.
By: Bill Wellock | Published: March 10, 2022 | 9:53 am | SHARE: The first COVID cases in the United States were confirmed in early 2020. Since then, the pandemic has raised questions about health care, education, civil rights and responsibilities and more.Florida State University experts are available to talk about the effort to develop vaccines and treatments for COVID-19 and the effects of the pandemic on the hospitality industry.
• Compared with individuals on dialysis who were not vaccinated against COVID-19, those who had received 2 mRNA vaccine doses were 69% and 83% less likely to become infected or experience severe disease, respectively. • There were no significant differences in vaccine effectiveness among age groups, mode of dialysis, or vaccine type.
Don't miss these articles in our Staff Picks channel
SARS-CoV-2 viruses can hide from recognition by the immune system.
Researchers at the Uniformed Services University in collaboration with University of Washington, have recently uncovered new details about how Nipah and Hendra viruses infect cells and the immune responses that can block them, which could ultimately lead to the development of new tactics to prevent and treat these deadly illnesses.
Two years after the early days of the COVID-19 crisis, a case study examines the successful response and leadership role of Rutgers related to vaccination and the safety of faculty, staff and students
With cold and flu season underway, plus the ongoing COVID-19 pandemic, infectious disease specialist Jeffrey Bender, MD, shares how to tell the difference between the illnesses, and the most important thing parents can do to keep children safe.
Following years of growing vaccine opposition and several outbreaks of measles--a vaccine-preventable disease--Facebook established in 2019 its first policy to stop the spread of misinformation about vaccines. Researchers at the George Washington University wondered if the new policies actually worked to stop the spread of misinformation. Jiayan Gu, PhD student along with Lorien Abroms, Professor of Prevention and Community Health and their colleagues created a new paradigm for evaluation of the policy. The team found that Facebook’s policy did reduce people’s interactions with vaccine misinformation.
Nirsevimab showed 74.5 percent efficacy against medically attended lower respiratory tract infections caused by respiratory syncytial virus (RSV) in healthy infants, according to an international, randomised, placebo-controlled Phase 3 clinical trial. It is the first potential immunization against RSV in the general infant population, with a single dose providing safe protection across the entire RSV season. Results were published in the New England Journal of Medicine.
Trauma patients treated and hospitalized in a Tennessee medical center had a 33% lower rate of COVID-19 vaccination than non-trauma patients who were hospitalized following treatment in the emergency department.
Two years after the pandemic began, the virus that causes COVID-19 is becoming a little easier to live with, thanks to medical innovations.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
